Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ETV
|
|||
| Former ID |
DIB000407
|
|||
| Drug Name |
Nemonaxacin
|
|||
| Indication | Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09; ICD-10: B95.62] | Phase 3 | [1] | |
| Company |
Warner Chilcott plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Topoisomerase IV (Stap-coc parC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02205112) A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP. U.S. National Institutes of Health. | |||
| REF 2 | In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.